Antibacterial agents: Selected publications

 

Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study
Vallejo-Torres L, Pujol M, Shaw E, Wiegand I, Vigo JM, Stoddart M, Grier S, Gibbs J, Vank C, Cuperus N, van den Heuvel L, Eliakim-Raz N, Carratala J, Vuong C, MacGowan A, Babich T, Leibovici L, Addy I, Morris S; RESCUING Study Group and Study Sites.
BMJ Open. 2018 Apr 12;8(4):e020251. doi: 10.1136/bmjopen-2017-020251.


Investigational drugs to treat methicillin-resistant Staphylococcus aureus
Vuong C, Yeh AJ, Cheung GY, Otto M.
Expert Opin Investig Drugs. 2016;25(1):73-93. doi: 10.1517/13543784.2016.1109077. Epub 2015 Nov 4.


The Innovative Medicines Initiative (IMI) New Drugs for Bad Bugs (ND4BB) programme – European Public-Private Partnerships for the Development of New Strategies to Tackle Antibiotic Resistance
Kostyanev T, deWinter R, Steel H, Ross S, O’Brien S, François B, Winterhalter M, Stavenger R, Karlén A, Harbarth S, Hackett J, Jafri H, Vuong C, MacGowan A, Witschi A, Angyalosi G, Elborn S, Bonten M, Goossens H, and for the ND4BB Consortia.
J Antimicrob Chemother. 2016 Feb;71(2):290-5. doi: 10.1093/jac/dkv339. Epub 2015 Nov 15.


How many modes of action should an antibiotic have?
Brötz-Oesterhelt H, Brunner NA.
Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30. Review.


Total synthesis and initial structure-activity relationships of longicatenamycin A
von Nussbaum F, Anlauf S, Freiberg C, Benet-Buchholz J, Schamberger J, Henkel T, Schiffer G, Häbich D.
ChemMedChem. 2008 Apr;3(4):619-26.


Structure and total synthesis of lysobactin (katanosin B)
von Nussbaum F, Anlauf S, Benet-Buchholz J, Häbich D, Köbberling J, Musza L, Telser J, Rübsamen-Waigmann H, Brunner NA.
Angew Chem Int Ed Engl. 2007;46(45):8548-52.